165901-26-8

Basic information

• Product Name: 1H-IMidazole, 2-(4-fluorophenyl)-4,5-dihydro-
• Synonyms: 1H-IMidazole, 2-(4-fluorophenyl)-4,5-dihydro-;4,5-dihydro-2-(2,4,6-trimethylphenyl)-1H-Imidazole
• CAS NO: 165901-26-8
• Molecular Formula: C₉H₉FN₂
• Molecular Weight: 164.1795632
• Mol File: 165901-26-8.mol

Chemical Properties

• Melting Point: 153 °C(Solv: cyclohexane (110-82-7))
• Boiling Point: 243.7±42.0 °C(Predicted)
• Appearance: /
• Density: 1.23±0.1 g/cm3(Predicted)
• PKA: 9.87±0.40(Predicted)
• CAS DataBase Reference: 1H-IMidazole, 2-(4-fluorophenyl)-4,5-dihydro-(CAS DataBase Reference)
• NIST Chemistry Reference: 1H-IMidazole, 2-(4-fluorophenyl)-4,5-dihydro-(165901-26-8)
• EPA Substance Registry System: 1H-IMidazole, 2-(4-fluorophenyl)-4,5-dihydro-(165901-26-8)

Safety Data

• Hazardous Substances Data: 165901-26-8(Hazardous Substances Data)

Usage

Uses

Used in Pharmaceutical Research and Drug Development:
1H-IMidazole, 2-(4-fluorophenyl)-4,5-dihydrois used as a key intermediate in the synthesis of potential antifungal and antimicrobial agents. Its unique structure allows for the development of new drugs that can target specific pathogens and combat drug-resistant strains.
Used in Agricultural Chemistry:
1H-IMidazole, 2-(4-fluorophenyl)-4,5-dihydromay also have applications in the field of agricultural chemistry. Its potential use in the development of new pesticides or fungicides could contribute to more effective crop protection and increased agricultural productivity.
Ongoing Research and Development:
The specific properties and uses of 1H-IMidazole, 2-(4-fluorophenyl)-4,5-dihydroare the subject of ongoing research and development efforts in various scientific disciplines. As our understanding of this compound grows, it may reveal additional applications and benefits in different industries.

Upstream product

• 1194-02-1 4-fluorobenzonitrile 
• 107-15-3 ethylenediamine 
• 42202-95-9 4-fluoro-N-hydroxybenzimidoyl chloride 
• 403-33-8 methyl 4-flurobenzoate 
• 22179-72-2 4-fluorothiobenzamide 
• 7119-23-5 2-Brom-3,3,3-trifluor-1-(4-fluorphenyl)-prop-1-en 
• 459-57-4 4-fluorobenzaldehyde 
• 766-98-3 1-ethynyl-4-fluorobenzene 
• 98-88-4 benzoyl chloride 
• 39833-45-9 3-(4-fluorophenyl)-1-phenylprop-2-yn-1-one 

Downstream Products

• 4278-08-4 2-(4-fluorophenyl)-1H-imidazole 
• 1441929-83-4 C₁₅H₁₃FN₄O₂ 
• 1441932-03-1 C₁₅H₁₅FN₄ 
• 1621586-60-4 2-(4-fluorophenyl)-1-(4-(methylsulfonyl)phenyl)-4,5-dihydro-1H-imidazole 
• 1621586-72-8 4-(2-(4-fluorophenyl)-4,5-dihydroimidazol-1-yl)benzenesulfonamide 

Relevant articles and documents

Benzamidine derivatives, preparation methods and applications

The present invention discloses benzamidine derivatives, preparation methods and applications. Benzamidine derivatives involved include benzamidine derivatives containing 1,2,4-triazole methyl and non-heterocyclically substituted benzamidine derivatives.

Structure-based design, synthesis and crystallization of 2-arylquinazolines as lipid pocket ligands of p38α MAPK

In protein kinase research, identifying and addressing small molecule binding sites other than the highly conserved ATP-pocket are of intense interest because this line of investigation extends our understanding of kinase function beyond the catalytic phosphotransfer. Such alternative binding sites may be involved in altering the activation state through subtle conformational changes, control cellular enzyme localization, or in mediating and disrupting protein-protein interactions. Small organic molecules that target these less conserved regions might serve as tools for chemical biology research and to probe alternative strategies in targeting protein kinases in disease settings. Here, we present the structure-based design and synthesis of a focused library of 2-arylquinazoline derivatives to target the lipophilic C-terminal binding pocket in p38α MAPK, for which a clear biological function has yet to be identified. The interactions of the ligands with p38α MAPK was analyzed by SPR measurements and validated by protein X-ray crystallography.

New Insights into the Role of Imidazolium-Based Promoters for the Electroreduction of CO2 on a Silver Electrode

The electrochemical reduction of CO2 to CO is a reaction of central importance for sustainable energy conversion and storage. Herein, structure-activity relationships of a series of imidazolium-based cocatalysts for this reaction are described,

Isoform-selective inhibitory profile of 2-imidazoline-substituted benzene sulfonamides against a panel of human carbonic anhydrases

A series of novel benzene sulfonamides (previously evaluated as selective cyclooxygenase-2 inhibitors) has been profiled against human carbonic anhydrases I, II, IV and VII in an attempt to observe the manifestation of the well established “tail” approach

Efficient synthesis of 2-imidazolines in the presence of molecular iodine under ultrasound irradiation

An efficient one-pot synthesis process for preparing 2-imidazolines from aldehydes and ethylenediamine using molecular iodine and potassium carbonate in absolute ethanol at 25-30°C under ultrasound irradiation is described. The synthetic strategy has the following advantages: mild conditions and low costs requirements, readily available catalyst, short reaction times, simplicity of operation, and good-to-excellent yields.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to pharmaceutical compositions for treating cancer comprising BRAF inhibitors, (e.g. vemurafenib) and/or MEK inhibitor, (e.g. trametinib, RO5068760), in combination with anti-tubulin compounds of the invention or other known tubulin inhibitors, and using such compositions for treating cancer such as melanoma, drug-resistant cancer, and cancer metastasis.

Dissecting alkynes: Full cleavage of polarized C≡C moiety via sequential bis-michael addition/retro-mannich cascade

The reaction of diaryl ketoalkynes with 1,2-diamino ethane leads to the full scission of the triple bond with the formation of acetophenone and imidazoline fragments. In this transformation, one of the alkyne carbons undergoes formal reduction with the formation of three C-H bonds, whereas the other carbon undergoes formal oxidation via the formation of three C-N bonds (one π and two σ). Computational analysis confirmed that the key fragmentation step proceeds via a six-membered TS in a concerted manner. Both amines are involved in the fragmentation: the N-H moiety of one amine transfers a proton to the developing negative charge at the enolate oxygen, while the other amine provides direct stereoelectronic assistance to the C-C bond cleavage via a hyperconjugative nN → σ*C-C interaction.

COMPOUNDS FOR TREATMENT OF CANCER

The present invention relates to novel compounds having anti-cancer activity, methods of making these compounds, and their use for treating cancer and drug-resistant tumors, e.g. melanoma, metastatic melanoma, drug resistant melanoma, prostate cancer and drug resistant prostate cancer.

Discovery of novel 2-aryl-4-benzoyl-imidazoles targeting the colchicines binding site in tubulin as potential anticancer agents

A series of 2-aryl-4-benzoyl-imidazoles (ABI) was synthesized as a result of structural modifications based on the previous set of 2-aryl-imidazole-4- carboxylic amide (AICA) derivatives and 4-substituted methoxylbenzoyl-aryl- thiazoles (SMART). The average IC50 of the most active compound (5da) was 15.7 nM. ABI analogues have substantially improved aqueous solubility (48.9 μg/mL for 5ga vs 0.909 μg/mL for SMART-1, 0.137 μg/mL for paclitaxel, and 1.04 μg/mL for combretastatin A4). Mechanism of action studies indicate that the anticancer activity of ABI analogues is through inhibition of tubulin polymerization by interacting with the colchicine binding site. Unlike paclitaxel and colchicine, the ABI compounds were equally potent against multidrug resistant cancer cells and the sensitive parental melanoma cancer cells. In vivo results indicated that 5cb was more effective than DTIC in inhibiting melanoma xenograph tumor growth. Our results suggest that the novel ABI compounds may be developed to effectively treat drug-resistant tumors.

Fragmentation of trifluoromethylated alkenes and acetylenes by N, N -binucleophiles. Synthesis of imidazolines or imidazolidines (Oxazolidines) controlled by substituent

The reaction of β-halogeno-β-polyfluoromethylstyrenes with N,N- or N,O-binucleophiles leads to unexpected fragmentation products (imidazolines) or to heterocyclization giving CF3-substituted imidazolidines (N,N-) and oxazolidines (N,O-) depending on aryl substituent. The scope and the reaction mechanism are discussed.